Skip to content
Screener

Zymeworks ZYME Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Amgen logo
AmgenAMGN
$00.0%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$00.0%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$00.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$00.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$4.6M-90.6%
Operating income-$42.2M-6,158%
Net income-$45.0M-2,043%
EPS (diluted)-$0.62-2,167%

Balance sheet

See full
Cash & equivalents$179.4M+82.6%
Total debt$16.0M-14.3%
Total equity$80.4M-76.0%
Total assets$397.0M-2.8%

Cash flow

See full
Operating cash flow-$31.9M-365%
CapEx$216.0K+1,250%
Free cash flow-$31.9M-376%

Valuation

See full
Market cap$1.67B+82.0%
Enterprise value$1.51B+79.8%
P/S45×+37.5×

Profitability

See full
Operating margin-419%-518pp
Net margin-404%-489pp
FCF margin-324.7%-366pp

Returns & leverage

See full
Return on equity-72.3%-117pp
Debt / equity0.2×+0.1×
Current ratio6.3×-1.4×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Zymeworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001937653-26-000047
AssetsJune 30,2026 / (unaudited)December 31,2025
Deferred tax liability3,7406,028
Total liabilities316,59578,026
Stockholders’ equity:
Common stock, $0.00001 par value; 900,000,000 authorized shares at June 30, 2026 and December 31, 2025, respectively; 71,412,072 and 74,638,413 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1,133,9591,105,176
Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of June 30, 2026 and December 31, 2025
Exchangeable shares, no par value, 550,000 and 553,184 issued and outstanding shares at June 30, 2026 and December 31, 2025, respectively7,8927,938
Additional paid-in capital116,450114,626
Accumulated other comprehensive loss(6,694)(6,079)

Item 1. Financial Statements

FAQ

What is Zymeworks's common stock, par value (in dollars per share)?
Zymeworks (ZYME) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
How has Zymeworks's common stock, par value (in dollars per share) changed year-over-year?
Zymeworks's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Zymeworks's common stock, par value (in dollars per share)?
Over 3 years (2022 to 2025), Zymeworks's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
What does common stock, par value (in dollars per share) mean?
Common stock, par value (in dollars per share)

Ask your AI about Zymeworks's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude